Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: PncA sequencing versus Bactec MGIT 960

Dmitry A. Maslov, Marina V. Zaîchikova, Larisa N. Chernousova, Kirill V. Shur, Olga B. Bekker, Tatiana G. Smirnova, Elena E. Larionova, Sofya N. Andreevskaya, Ying Zhang, Valery N. Danilenko

Research output: Contribution to journalArticle

Abstract

Summary Resistance to pyrazinamide (PZA) may impact clinical outcome of anti-tuberculosis chemotherapy. PZA susceptibility testing using MGIT 960 is not reliable and little information is available on the prevalence of PZA resistance in Russia. A collection of 64 clinical isolates of Mycobacterium tuberculosis, including 35 multidrug resistant and extensively drug-resistant (MDR/XDR), was analyzed for PZA resistance using MGIT 960, Wayne test, and sequencing of PZA resistance genes pncA, rpsA and panD. In addition, we analyzed 519 MDR-TB strains for susceptibility to PZA by MGIT 960. Sequencing of pncA revealed 17 of 25 (68%) MDR strains and all 10 XDR strains harboring pncA mutations. A correlation of φ = 0.81 between MGIT 960 and pncA sequencing was observed. Mutations in rpsA and panD not associated with PZA resistance as defined by MGIT 960 were identified. We found 1 PZA-resistant strain without mutations in known PZA resistance genes. Almost 73% of MDR-TB strains isolated in Moscow, Russia, were PZA-resistant by MGIT 960 testing of 519 MDR-TB clinical isolates. Further studies are needed to determine the role of rpsA and panD mutations in possible low-level PZA resistance and to identify the molecular basis of new PZA resistance in the isolate without known PZA resistance mutations.

Original languageEnglish (US)
Pages (from-to)608-612
Number of pages5
JournalTuberculosis
Volume95
Issue number5
DOIs
StatePublished - Sep 1 2015

Fingerprint

Pyrazinamide
Mycobacterium tuberculosis
Mutation
Russia
Moscow
Genes

Keywords

  • Drug susceptibility testing
  • MGIT960
  • pncA
  • Pyrazinamide
  • Resistance
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Maslov, D. A., Zaîchikova, M. V., Chernousova, L. N., Shur, K. V., Bekker, O. B., Smirnova, T. G., ... Danilenko, V. N. (2015). Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: PncA sequencing versus Bactec MGIT 960. Tuberculosis, 95(5), 608-612. https://doi.org/10.1016/j.tube.2015.05.013

Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates : PncA sequencing versus Bactec MGIT 960. / Maslov, Dmitry A.; Zaîchikova, Marina V.; Chernousova, Larisa N.; Shur, Kirill V.; Bekker, Olga B.; Smirnova, Tatiana G.; Larionova, Elena E.; Andreevskaya, Sofya N.; Zhang, Ying; Danilenko, Valery N.

In: Tuberculosis, Vol. 95, No. 5, 01.09.2015, p. 608-612.

Research output: Contribution to journalArticle

Maslov, DA, Zaîchikova, MV, Chernousova, LN, Shur, KV, Bekker, OB, Smirnova, TG, Larionova, EE, Andreevskaya, SN, Zhang, Y & Danilenko, VN 2015, 'Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: PncA sequencing versus Bactec MGIT 960', Tuberculosis, vol. 95, no. 5, pp. 608-612. https://doi.org/10.1016/j.tube.2015.05.013
Maslov DA, Zaîchikova MV, Chernousova LN, Shur KV, Bekker OB, Smirnova TG et al. Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: PncA sequencing versus Bactec MGIT 960. Tuberculosis. 2015 Sep 1;95(5):608-612. https://doi.org/10.1016/j.tube.2015.05.013
Maslov, Dmitry A. ; Zaîchikova, Marina V. ; Chernousova, Larisa N. ; Shur, Kirill V. ; Bekker, Olga B. ; Smirnova, Tatiana G. ; Larionova, Elena E. ; Andreevskaya, Sofya N. ; Zhang, Ying ; Danilenko, Valery N. / Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates : PncA sequencing versus Bactec MGIT 960. In: Tuberculosis. 2015 ; Vol. 95, No. 5. pp. 608-612.
@article{c80b18add66249d18139536760840c0b,
title = "Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: PncA sequencing versus Bactec MGIT 960",
abstract = "Summary Resistance to pyrazinamide (PZA) may impact clinical outcome of anti-tuberculosis chemotherapy. PZA susceptibility testing using MGIT 960 is not reliable and little information is available on the prevalence of PZA resistance in Russia. A collection of 64 clinical isolates of Mycobacterium tuberculosis, including 35 multidrug resistant and extensively drug-resistant (MDR/XDR), was analyzed for PZA resistance using MGIT 960, Wayne test, and sequencing of PZA resistance genes pncA, rpsA and panD. In addition, we analyzed 519 MDR-TB strains for susceptibility to PZA by MGIT 960. Sequencing of pncA revealed 17 of 25 (68{\%}) MDR strains and all 10 XDR strains harboring pncA mutations. A correlation of φ = 0.81 between MGIT 960 and pncA sequencing was observed. Mutations in rpsA and panD not associated with PZA resistance as defined by MGIT 960 were identified. We found 1 PZA-resistant strain without mutations in known PZA resistance genes. Almost 73{\%} of MDR-TB strains isolated in Moscow, Russia, were PZA-resistant by MGIT 960 testing of 519 MDR-TB clinical isolates. Further studies are needed to determine the role of rpsA and panD mutations in possible low-level PZA resistance and to identify the molecular basis of new PZA resistance in the isolate without known PZA resistance mutations.",
keywords = "Drug susceptibility testing, MGIT960, pncA, Pyrazinamide, Resistance, Tuberculosis",
author = "Maslov, {Dmitry A.} and Za{\^i}chikova, {Marina V.} and Chernousova, {Larisa N.} and Shur, {Kirill V.} and Bekker, {Olga B.} and Smirnova, {Tatiana G.} and Larionova, {Elena E.} and Andreevskaya, {Sofya N.} and Ying Zhang and Danilenko, {Valery N.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.tube.2015.05.013",
language = "English (US)",
volume = "95",
pages = "608--612",
journal = "Tuberculosis",
issn = "1472-9792",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates

T2 - PncA sequencing versus Bactec MGIT 960

AU - Maslov, Dmitry A.

AU - Zaîchikova, Marina V.

AU - Chernousova, Larisa N.

AU - Shur, Kirill V.

AU - Bekker, Olga B.

AU - Smirnova, Tatiana G.

AU - Larionova, Elena E.

AU - Andreevskaya, Sofya N.

AU - Zhang, Ying

AU - Danilenko, Valery N.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Summary Resistance to pyrazinamide (PZA) may impact clinical outcome of anti-tuberculosis chemotherapy. PZA susceptibility testing using MGIT 960 is not reliable and little information is available on the prevalence of PZA resistance in Russia. A collection of 64 clinical isolates of Mycobacterium tuberculosis, including 35 multidrug resistant and extensively drug-resistant (MDR/XDR), was analyzed for PZA resistance using MGIT 960, Wayne test, and sequencing of PZA resistance genes pncA, rpsA and panD. In addition, we analyzed 519 MDR-TB strains for susceptibility to PZA by MGIT 960. Sequencing of pncA revealed 17 of 25 (68%) MDR strains and all 10 XDR strains harboring pncA mutations. A correlation of φ = 0.81 between MGIT 960 and pncA sequencing was observed. Mutations in rpsA and panD not associated with PZA resistance as defined by MGIT 960 were identified. We found 1 PZA-resistant strain without mutations in known PZA resistance genes. Almost 73% of MDR-TB strains isolated in Moscow, Russia, were PZA-resistant by MGIT 960 testing of 519 MDR-TB clinical isolates. Further studies are needed to determine the role of rpsA and panD mutations in possible low-level PZA resistance and to identify the molecular basis of new PZA resistance in the isolate without known PZA resistance mutations.

AB - Summary Resistance to pyrazinamide (PZA) may impact clinical outcome of anti-tuberculosis chemotherapy. PZA susceptibility testing using MGIT 960 is not reliable and little information is available on the prevalence of PZA resistance in Russia. A collection of 64 clinical isolates of Mycobacterium tuberculosis, including 35 multidrug resistant and extensively drug-resistant (MDR/XDR), was analyzed for PZA resistance using MGIT 960, Wayne test, and sequencing of PZA resistance genes pncA, rpsA and panD. In addition, we analyzed 519 MDR-TB strains for susceptibility to PZA by MGIT 960. Sequencing of pncA revealed 17 of 25 (68%) MDR strains and all 10 XDR strains harboring pncA mutations. A correlation of φ = 0.81 between MGIT 960 and pncA sequencing was observed. Mutations in rpsA and panD not associated with PZA resistance as defined by MGIT 960 were identified. We found 1 PZA-resistant strain without mutations in known PZA resistance genes. Almost 73% of MDR-TB strains isolated in Moscow, Russia, were PZA-resistant by MGIT 960 testing of 519 MDR-TB clinical isolates. Further studies are needed to determine the role of rpsA and panD mutations in possible low-level PZA resistance and to identify the molecular basis of new PZA resistance in the isolate without known PZA resistance mutations.

KW - Drug susceptibility testing

KW - MGIT960

KW - pncA

KW - Pyrazinamide

KW - Resistance

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84940460611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940460611&partnerID=8YFLogxK

U2 - 10.1016/j.tube.2015.05.013

DO - 10.1016/j.tube.2015.05.013

M3 - Article

C2 - 26071666

AN - SCOPUS:84940460611

VL - 95

SP - 608

EP - 612

JO - Tuberculosis

JF - Tuberculosis

SN - 1472-9792

IS - 5

ER -